Recombinant Fusion Polypeptides Enable Bacteroides Cargo Secretion

USPTO published patent application US20260097087A1 disclosing recombinant fusion polypeptides engineered with secretion domains and heterologous cargo domains for enabling protein secretion from Bacteroides cells into extracellular environments. The application covers methods of manufacturing and using these fusion polypeptides for therapeutic applications including treatment of diseases and disorders. CPC classifications span multiple technical areas including microbiology, protein engineering, and pharmaceutical compositions.

Biotechnology companies developing microbial protein expression systems, live biotherapeutic products, or gut microbiome-based therapeutics should review this application for potential freedom-to-operate concerns. Research institutions working with Bacteroides host systems may need to consider licensing implications. The broad claim scope covering both composition and method-of-use could affect competitive positioning in the engineered microbiome space.